PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

The Boss Incretin Stack

The **Retatrutide / Tirzepatide Incretin Duo** is a research formulation combining two long-acting, synthetic 39-amino-acid incretin receptor agonists: **Tirzepatide** (a dual GIP/GLP-1 receptor agonist) and **Retatrutide** (a triple GIP/GLP-1/glucagon receptor agonist).

1. Chemical Structure and Biochemistry

Both peptides share a similar architectural blueprint derived from modified human GIP backbones engineered for once-weekly pharmacokinetics.

  • DPP-4 Resistance: Both Retatrutide and Tirzepatide incorporate non-canonical $\alpha$-aminoisobutyric acid (Aib) substitutions to block rapid proteolytic cleavage by dipeptidyl peptidase-4 (DPP-4).
  • Albumin-Binding Acylation: Each sequence is conjugated via a hydrophilic linker to a C20 fatty diacid moiety, enabling reversible binding to plasma serum albumin and extending elimination half-lives to approximately 5 days (Tirzepatide) and 6 days (Retatrutide).

2. Mechanism of Action

Combining Tirzepatide and Retatrutide creates overlapping activation across two incretin receptors alongside selective addition of a third metabolic pathway:

  • GLP-1 Receptor (GLP-1R) — Shared: Both compounds stimulate glucose-dependent insulin secretion, slow gastric emptying, and activate hypothalamic and brainstem satiety circuits to reduce energy intake.
  • GIP Receptor (GIPR) — Shared: Both exhibit high potency at GIPR, enhancing postprandial insulin sensitivity in adipose tissue and augmenting GLP-1-mediated appetite suppression.
  • Glucagon Receptor (GCGR) — Retatrutide Only: Retatrutide uniquely introduces GCGR agonism, promoting resting energy expenditure, hepatic $\beta$-oxidation, and rapid clearance of intrahepatic triglycerides.

3. Research and Applications

While Tirzepatide is FDA-approved (Mounjaro, Zepbound) and Retatrutide is undergoing Phase 3 clinical trials as monotherapies, their co-formulation exists strictly in non-clinical experimental contexts.

  • Receptor Ratio Modulation: Investigated conceptually in metabolic research to adjust the ratio of GIP/GLP-1 signaling relative to glucagon receptor stimulation, which may influence glycemic stability, appetite suppression, and thermogenesis.
  • Pharmacology & Safety Considerations: Because both peptides compete for and saturate GLP-1R and GIPR, co-administration has not been evaluated in formal human clinical trials and presents overlapping gastrointestinal and metabolic tolerability considerations.

Note: Co-formulated Retatrutide/Tirzepatide blends are unapproved experimental research preparations.

Tags: Retatrutide Tirzepatide Incretin-Duo GLP-1R GIPR GCGR dual-agonist triple-agonist incretin-mimetic metabolic-research weight-management-peptide